TRDX Daily US Market Briefing
BULLISHupdated 8:11 AM PT
Sector Heatmap
Breadth (prior session): Materials (+1.85%) and Healthcare (+1.45%) lead by a wide margin — Materials tracking gold/silver’s safe-haven bid, Healthcare riding the Moderna/Merck Phase 3 melanoma-vaccine win — while Technology (+0.58%) and Industrials (+0.54%) hold a firm but more modest advance. Only Communication Services (-0.12%) is red. Broad-based green across 10 of 11 sectors confirms today’s bullish regime call.
Market Bias
- Futures (+8): S&P +0.43%, Nasdaq +0.39%, Dow +0.56%, Russell 2000 +0.80% — broad-based pre-market strength across all four indices, though gains are moderate rather than explosive.
- VIX (0): 15.38 (-2.97%) — sits right at the 15-handle, still technically inside the neutral 15-20 band even as it eases.
- Newsletter tone (+3): MarketWatch’s Fundstrat technician calls the yield selloff “an opportunity, not a warning” and expects a push to new highs; Bloomberg confirms markets steadied after the Canada-tariff pause — tempered by real, unresolved AI-capex/bond-yield anxiety in the same coverage.
- Stocktwits sentiment (+2): Top-searched tickers (NVDA, SPCX, MU, TSLA) skew AI/growth — active risk appetite, not euphoria.
- CNN Fear & Greed (+5): Reads ~59, Greed — still leaning optimistic despite this week’s bond-yield jitters.
Overall Economic Summary
Markets are staging a tentative bounce after Tuesday’s yield-driven selloff. Trump paused the 50% Canada tariffs for three days citing a tentative deal — averting the hard midnight deadline that was hanging over the tape — and a report that Treasury will expand its buyback support for longer-dated debt is helping calm the bond market. The combination has futures broadly higher pre-market (S&P +0.43%, Nasdaq +0.39%, Dow +0.56%, Russell 2000 +0.80%), though the underlying yield story isn’t fully resolved: the 10-year sits at 4.647% (still up sharply on the month), and gold ($4,474.80, +1.23%) and silver ($64.96, +1.43%) are both catching a real safe-haven bid — a sign the debt-funded-AI-capex anxiety that hit tech this week hasn’t disappeared, it’s just paused.
Today’s calendar is dominated by two events that will decide whether that pause holds: the FOMC’s July 28-29 meeting minutes (2:00 PM ET) — a meeting that produced the first three-way, same-direction hawkish dissent since September 2016 (Presidents Logan, Hammack and Kashkari all pushed for a 25bp hike) — and a $16B 20-year Treasury auction (1:00 PM ET), a fresh referendum on demand for long-dated US debt right after this week’s rout pushed 30-year yields to their highest level in nearly two decades. A weak auction or a hawkish-leaning minutes read could reignite the yield pressure that capped tech on Tuesday; a clean auction plus a more balanced minutes tone is a straightforward risk-on catalyst into the close.
Retail earnings are the other big swing factor and they’re sending a genuinely bifurcated signal: Lowe’s trimmed its full-year sales and EPS guidance on soft DIY spending, but Target beat comps (+3.8% vs. +2.5% est.) and raised its outlook, and Estée Lauder crushed both lines (adj. EPS $0.39 vs. $0.32 est., revenue $3.63B vs. $3.55B est., FY27 EPS guide of $3.10-3.35 above consensus) and is up double digits pre-market. Add Analog Devices’ record fiscal Q3 (revenue $4.02B, +40% YoY, led by Data Center/Industrial) after Tuesday’s close and a landmark Phase 3 win for Moderna’s personalized mRNA melanoma vaccine alongside Merck’s Keytruda, and the through-line is clear: real, fundamental beat-and-raise catalysts are winning out over macro noise today — exactly the setup this bullish-regime scan is built to find.
Market Sentiment
Futures point to a broadly higher open: S&P 500 +0.43%, Nasdaq 100 +0.39%, Dow +0.56%. Filtering long setups first today, with one confirmed counter-trend short (NBIS) carrying a fresh, credible bearish catalyst — Michael Burry publicly expanding his short thesis against the name — strong enough to include despite the broadly bullish tape.
Key Market Stats
Economic Calendar
| Time (ET) | Event | Consensus | Prior | Impact |
|---|---|---|---|---|
| 1:00 PM | 20-Year Treasury Note Auction ($16B) | — | — | HIGH |
| 2:00 PM | FOMC Minutes (July 28-29 meeting) | — | — | HIGH |
| All Day | US-Canada tariff talks (50% duties paused 3 days pending final deal) | — | — | MED |
Today’s Earnings
Fiscal Q4 beat on both lines and FY27 adj. EPS guide of $3.10-3.35 landed above the $3.18 consensus midpoint, driven by resilient premium fragrance demand and continued China strength under the CEO’s turnaround plan. Shares +12.5% pre-market — the biggest gapper on today’s scanner.
Beat comps and raised its annual net-sales growth outlook to ~5%, a genuine read-through on discretionary consumer health that supports the broader risk-on tone this morning.
The soft spot in today’s retail cluster — trimmed FY sales guide to ~$92B (from $92-94B) and comp guide to flat (from flat-to-+2%) on continued weak DIY spending. A useful counterweight to TGT/EL — today’s consumer picture is bifurcated, not uniformly strong.
Shares -3.9% pre-market on a softer near-term profit outlook despite resilient value-shopper demand and a raised full-year guide — a sell-the-guide-caveat reaction, not a fundamental miss.
Key Events Today
This meeting produced the first three-way, same-direction hawkish dissent since September 2016 — regional presidents Logan, Hammack and Kashkari all pushed for a 25bp hike. Traders will parse the minutes for how widely that hawkish view was shared across the broader committee; a hawkish tilt is a direct threat to the bond-market calm underpinning today’s bounce.
Moderna’s personalized mRNA cancer vaccine (Intismeran), used alongside Merck’s Keytruda, met both the primary goal (reducing melanoma recurrence) and secondary goal (preventing spread) in a Phase 3 study. MRNA +~60% and MRK +7.5% pre-market — a major oncology catalyst rippling through the whole cancer-therapeutics and diagnostics complex, including today’s TEM setup.
The 50% Section 338 duties that were set to hit at midnight tonight are paused for three days pending a final deal; auto and lumber rules remain the sticking points. Removes an immediate tail risk but doesn’t resolve it — watch for headlines the rest of the week.
~319M shares held by family offices (~$3.8B) unlock tomorrow, Aug 20. Today is the last full session before that supply hits the float — directly relevant to the SPCX setup below.
TRDX Top 10 Movers
Built from today’s Pre-Market Gappers I/II/III scanner lists, the live desk watchlist, and user-flagged names. Bullish regime → longs lead, with one user-flagged counter-trend short (NBIS) carrying a fresh, confirmed bearish catalyst strong enough to hold against the tape.
CATALYST: Still digesting the blowout Q2 print (EPS $5.75, +218% vs. est.; AWS growth +36.8% YoY, its fastest pace in 18 quarters) and a raised FY26 capex guide to $220B (from $200B) on rising memory costs. TS2’s AI model portfolio ranks AMZN a #2 Strong Buy (89/100).
WHY IT’S MOVING: No fresh scanner-level gap — this is a clean ORB setup on the watchlist, riding the same AI-capex-conviction wave lifting Materials/Tech today, with Prime Day data, the Project Kuiper launch cadence and AWS AI-chip adoption metrics as the next catalysts on deck.
KEY DAILY PRICE LEVELS: VWAP anchor ~$259.5; expect a tight opening range of $256-$263 absent a fresh catalyst. Bias: long the reclaim of the opening range high; this is a breakout-confirmation trade, not a gap-and-go.
SUPPORT & RESISTANCE: Support: $257.73 (today’s premarket low, ~est.), $250 (round number). Resistance: $262.18 (today’s premarket high, ~est.), $270.
CATALYST: Buying the competitive-pressure dip ahead of the Aug 26 print — a Jefferies note flagged AMD’s Advancing AI 2026 roadmap as closing the gap in some segments, and Nvidia disclosed a fresh $21B stake in SpaceX at quarter-end. New open-source Omniverse Agent Toolkit libraries (SIGGRAPH 2026) extend the software moat.
WHY IT’S MOVING: Sits inside the same AI-capex-anxiety complex that hit tech Tuesday, but as the sector’s toll-taker rather than a spender — a classic buy-the-dip-into-a-known-catalyst setup with the Aug 26 earnings binary now one week out.
KEY DAILY PRICE LEVELS: VWAP anchor ~$220; expect an opening range of $215-$225. Bias: long dips toward VWAP while price holds the $215 area into next week’s print.
SUPPORT & RESISTANCE: Support: $215 (round-number shelf, ~est.), $205 (prior base). Resistance: $225 (recent swing high, ~est.), $235.
CATALYST: More than 1,500 institutional investors disclosed fresh positions on Aug 17, and the company just signed a new satellite-launch customer (Vietnam’s VinSpace, for 2027). 28 of 30 covering analysts rate the stock Buy.
WHY IT’S MOVING: Institutional accumulation is squaring off against tomorrow’s (Aug 20) ~319M-share, ~$3.8B family-office unlock — today’s the last clean session to position ahead of that supply event, and the buy-side flow suggests the market isn’t bracing for a dump.
KEY DAILY PRICE LEVELS: VWAP anchor ~$143.5; expect an opening range of $139-$147 (yesterday’s range was $139.41-$146.46). Bias: long while holding above $139.41; tighten stops or trim into strength ahead of tomorrow’s unlock.
SUPPORT & RESISTANCE: Support: $139.41 (yesterday’s low), $130 (round number). Resistance: $146.46 (yesterday’s high), $155.
CATALYST: Unveiled a new AI-focused memory infrastructure platform (Bravera SC6 SSD controllers, Structera X memory expansion, Photonic Fabric optical architecture) targeting hyperscale/agentic-AI bottlenecks at the FMS 2026 conference, plus a $250M three-year India R&D expansion. TD Cowen raised its target to $225-$256 range.
WHY IT’S MOVING: A genuine product-cycle catalyst landing one week ahead of the Aug 27 earnings print — the market is pricing in real AI-infrastructure share gains, not just pre-earnings positioning.
KEY DAILY PRICE LEVELS: VWAP anchor ~$216; expect an opening range of $205-$230 given the $17.53 ATR. Bias: long dips toward VWAP while holding above $205 into the Aug 27 print.
SUPPORT & RESISTANCE: Support: $205 (pre-gap base, ~est.), $190. Resistance: $234 (yesterday’s spike high, ~est.), $250 (average analyst target).
CATALYST: Fifth straight record-revenue quarter (Q2 sales +86% YoY to $191.9M, adj. EPS $0.06 beat) with a strong Q3 guide ($255-290M rev, $0.11-0.26 adj. EPS). Ramping 800G/1.6T/1.8GHz optics for AI data centers, with demand seen exceeding capacity through mid-2027. A reported draft FCC ban on new Chinese optical transceivers is an added structural tailwind.
WHY IT’S MOVING: Continuation of the post-earnings AI-optics markup — real backlog and a regulatory tailwind (China-transceiver ban) rather than a one-day pop, extending the run that started Aug 10-14.
KEY DAILY PRICE LEVELS: VWAP anchor ~$131.5; expect an opening range of $115-$148 given the $16.71 ATR. Bias: long dips toward VWAP while the AI-optics theme holds.
SUPPORT & RESISTANCE: Support: $115 (recent base, ~est.), $100. Resistance: $155 (Aug 14 spike area, ~est.), $178 (Raymond James target).
CATALYST: Record Q2 revenue and profitability on surging indium-phosphide (InP) demand for AI-data-center lasers; capacity set to more than double by 2027. Fresh reports flag a looming InP price hike, with the stock having already popped 19.8% on the news. Needham, Wedbush, Northland and Craig-Hallum all rate it Buy.
WHY IT’S MOVING: A genuine supply-constrained-materials story inside the AI-optics complex — same structural demand driver as AAOI/MRVL today, with pricing power now entering the thesis on top of volume growth.
KEY DAILY PRICE LEVELS: VWAP anchor ~$82.3; expect an opening range of $72-$93 given the $10.99 ATR. Bias: long dips toward VWAP while the InP shortage narrative holds.
SUPPORT & RESISTANCE: Support: $72 (pre-breakout base, ~est.), $65. Resistance: $95 (recent high, ~est.), $110.
CATALYST: Fiscal Q4 beat-and-raise (adj. EPS $0.39 vs $0.32 est., revenue $3.63B vs $3.55B est.); FY27 adj. EPS guide of $3.10-3.35 lands above the $3.18 consensus midpoint. Management points to resilient premium fragrance demand and continued China turnaround momentum.
WHY IT’S MOVING: The single largest pre-market gap on today’s entire scanner (+12.54%) — a clean, unambiguous beat-and-raise with guidance ahead of Street numbers, exactly the profile this bullish-regime scan is designed to surface first.
KEY DAILY PRICE LEVELS: VWAP anchor ~$84.3; expect an opening range of $80-$88 given the $2.44 ATR. Bias: long the reclaim of the pre-market high; this is a gap-and-go continuation setup.
SUPPORT & RESISTANCE: Support: $80 (round number/pre-gap base, ~est.), $75 (prior consolidation). Resistance: $88 (pre-market high, ~est.), $95.
CATALYST: Riding a strong sympathy bid off this morning’s Moderna/Merck Phase 3 melanoma-vaccine win (see Key Events) — Tempus’s core business is AI-driven genomic profiling and companion diagnostics for oncology, putting it directly in the read-through path of any major cancer-therapeutics data win.
WHY IT’S MOVING: Second-largest pre-market gap on today’s scanner; a sector-rotation trade into oncology-diagnostics names as Healthcare (+1.45%) leads the sector heatmap, even though the company’s own most recent analyst actions (Piper Sandler, JPMorgan) were neutral Holds earlier this month.
KEY DAILY PRICE LEVELS: VWAP anchor ~$49.4; expect an opening range of $44-$54 given the $3.22 ATR. Bias: long the sympathy move while Healthcare sector strength persists; this is a news-driven rotation trade, not a company-specific catalyst — size accordingly.
SUPPORT & RESISTANCE: Support: $44 (pre-gap base, ~est.), $40.77 (52-week low). Resistance: $54 (pre-market high, ~est.), $58.
CATALYST: Gained 4.6% Monday into today’s FOMC minutes (2:00 PM ET), with improving crypto sentiment offering support. The next hard catalyst is the Sept 16 Arc mainnet launch, with BlackRock and Visa named as initial partners.
WHY IT’S MOVING: A rate-sensitive, crypto-adjacent name trading directly on today’s FOMC-minutes outcome — a dovish-leaning read is a clean tailwind for CRCL given its stablecoin-reserve-yield business model; a hawkish surprise is the single biggest risk to this long today.
KEY DAILY PRICE LEVELS: VWAP anchor ~$75 (~est.); expect elevated volatility around the 2:00 PM ET minutes release regardless of direction. Bias: long into the print with a defined stop, given the binary nature of today’s catalyst.
SUPPORT & RESISTANCE: Support: $71.19 (Monday’s close, ~est.), $68.90 (recent intraday low, ~est.). Resistance: $75 (round number, ~est.), $80.
CATALYST: Michael Burry has continued adding to his short position against Nebius, reiterating that the setup is “what the top of a boom looks like.” This follows a +34% single-day post-earnings spike on Aug 12 that has since partially unwound, even as sell-side targets keep climbing (Northland $410, Baird $340, BofA $310).
WHY IT’S MOVING: A high-conviction, name-specific bearish catalyst from a well-known short-seller landing right as the stock gives back its post-earnings spike — a clean counter-trend short even against today’s broadly bullish tape, and the one name on this list where the risk/reward favors fading strength rather than buying it.
KEY DAILY PRICE LEVELS: VWAP anchor ~$248.4; expect an opening range of $222-$274 given the outsized $26.05 ATR. Bias: short failed reclaims of VWAP; cover into the $220-230 shelf.
SUPPORT & RESISTANCE: Support: $230 (early-August base, ~est.), $220. Resistance: $268 (recent swing high, ~est.), $277.68 (Aug 14 high).
Research Themes
MRVL, AAOI and AXTI are all gapping hard on genuine AI-data-center demand catalysts — a new memory infrastructure platform, record optics revenue with a China-transceiver regulatory tailwind, and an indium-phosphide supply squeeze, respectively. This is the picks-and-shovels layer of the AI trade, and all three are confirming each other today.
Tickers: MRVL, AAOI, AXTI
Moderna’s Phase 3 melanoma-vaccine win alongside Merck’s Keytruda is the day’s single biggest healthcare catalyst, and it’s rippling into the broader cancer-therapeutics/diagnostics complex — Tempus AI’s genomic-profiling and companion-diagnostics business sits squarely in that read-through path, helping explain why Healthcare (+1.45%) is the second-best sector today.
Tickers: TEM
AMZN and NVDA are both still nursing this week’s AI-capex-anxiety pullback but are positioned as the highest-quality names to own into confirmed near-term catalysts — NVDA’s Aug 26 earnings print and AMZN’s ongoing AWS/Kuiper cadence. SPCX rounds out the growth complex, riding heavy institutional accumulation into tomorrow’s share-unlock event.
Tickers: AMZN, NVDA, SPCX
The Days Ahead
| Date | Event / Description |
|---|---|
| Thu, Aug 20 | SPCX share-unlock ~319M shares (~$3.8B) held by family offices become eligible to trade — the key overhang risk on today’s SPCX long. |
| Fri, Aug 21 | Weekly options expiration Standard OpEx flow can add volatility into the close. |
| Mon, Aug 24 | Retail earnings follow-through Watch for continued commentary on the bifurcated consumer signal from today’s LOW/TGT/EL/TJX cluster. |
| Wed, Aug 26 | NVDA & CRWD earnings (same night) The single biggest catalyst of the month for the entire AI-infrastructure trade — directly relevant to today’s NVDA long. |
| Thu, Aug 27 | MRVL earnings Binary catalyst for a name already on today’s Top 10 — see Top 10 Movers. |
| Thu-Sat, Aug 27-29 | Jackson Hole Economic Policy Symposium Theme: “Financial Innovation: Implications for Payments and Policy.” Fed Chair Kevin Warsh delivers his first Jackson Hole keynote as chair Friday, Aug 28 — a major rate-path catalyst. |
| Thu, Sep 3 | DELL earnings Melius Research has its target at $650 (from $565) citing Nvidia Vera Rubin rack shipments. |
| Wed, Sep 16 | CRCL Arc mainnet launch Circle’s next hard catalyst, with BlackRock and Visa as initial partners — the forward thesis behind today’s CRCL long. |